Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady

Impact · against what's priced in

Hims & Hers faces a significant valuation reset as structural gross margin collapse and subscriber losses undermine the growth and margin assumptions the market was already skeptical of. Conversely, the news is non-material for Eli Lilly, as Hims & Hers' transition to branded GLP-1s merely confirms Lilly's existing market dominance.

HIMS−0.90

Challenges what's priced in

The price assumes